Growth Investment Partners (GIP) Ghana, an investment platform established by British International Investment (BII), has announced a strategic investment in mPharma Ghana, one of Africa’s leading health-tech innovators. This funding will accelerate mPharma’s ambitious growth plans, particularly its expansion into Francophone West Africa.
The capital injection will enable mPharma to extend its QualityRx franchise model into new markets, including Togo and Benin, while improving inventory efficiency across its rapidly growing multi-pharmacy network. Notably, more than half of the funding is earmarked for expansion in Francophone West Africa, where demand for reliable and affordable pharmaceutical services continues to rise.
Founded in 2013, mPharma has emerged as a pioneer in addressing one of Africa’s most pressing healthcare challenges—medicine affordability and accessibility. The company operates an asset-light franchise model, allowing independent pharmacies to join its Mutti brand network. Through proprietary software, mPharma optimizes inventory management, pricing, and supply chain operations, ensuring cost-effective and timely delivery of medicines.
Jacob Kholi, Chief Executive and Investment Officer at GIP Ghana, highlighted the impact of the investment:
Our goal is to back enterprises that improve essential services for ordinary people. This expansion will help communities gain better access to quality medicines while strengthening the resilience of local health systems.
Kwesi Arhin, CEO of mPharma, emphasized the strategic importance of the partnership:
Access to affordable medicines remains one of Africa’s most pressing healthcare challenges. With GIP’s support, we can scale our partnerships with pharmacies and healthcare providers to ensure equitable access to quality care across Ghana and Francophone West Africa.
